Mesothelin-CAR-T Cell Immunotherapy is under clinical development by Fapon Biotherapy and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mesothelin-CAR-T Cell Immunotherapy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesothelin-CAR-T Cell Immunotherapy overview
The therapeutic candidate is under development for the treatment of pancreatic cancer and solid tumors. It comprises of T-cells genetically modified to express chimeric antigen receptors (CARs) targeting cell expressing mesothelin.
Fapon Biotherapy overview
Fapon Biotherapy a biotechnology research company which focuses on R&D and services, in vitro diagnostic, biological therapy, precise diagnosis and treatment. The company is headquartered in Dongguan, Guangdong, China.
For a complete picture of Mesothelin-CAR-T Cell Immunotherapy’s drug-specific PTSR and LoA scores, buy the report here.